Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

BACKGROUND: Safety and immunogenicity of BNT162b2 mRNA vaccine are unknown in hematological patients; both were evaluated prospectively in 42 patients with multiple myeloma (MM) and 50 with myeloproliferative malignancies (MPM) (20 chronic myeloid leukemias and 30 myeloproliferative neoplasms), all...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Hematol Oncol
Главные авторы: Pimpinelli, Fulvia, Marchesi, Francesco, Piaggio, Giulia, Giannarelli, Diana, Papa, Elena, Falcucci, Paolo, Pontone, Martina, Di Martino, Simona, Laquintana, Valentina, La Malfa, Antonia, Di Domenico, Enea Gino, Di Bella, Ornella, Falzone, Gianluca, Ensoli, Fabrizio, Vujovic, Branka, Morrone, Aldo, Ciliberto, Gennaro, Mengarelli, Andrea
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2021
Предметы:
Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8128283/
https://ncbi.nlm.nih.gov/pubmed/34001183
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-021-01090-6
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы